Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lin, Ting Tse ^a   Chiang, Jiun Yang ^a   Liao, Min Tsun ^a   Tsai, Chia Ti ^a   Hwang, Juey Jen ^a   Chiang, Fu Tien ^a   Lin, Jiunn Lee ^a   Lin, Lian Yu ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADVERSE EFFECTS; ATRIAL FIBRILLATION; COMPLICATION; FEMALE; HEALTH SURVEY; HEMODIALYSIS; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; MALE; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODEL; RISK; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; POPULATION SURVEILLANCE; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK; TREATMENT OUTCOME;

EID: 84949595541     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17731     Document Type: Article

References (54)

1. Rostock, T. et al. Atrial fibrillation begets atrial fibrillation in the pulmonary veins on the impact of atrial fibrillation on the electrophysiological properties of the pulmonary veins in humans. J Am Coll Cardiol. 51, 2153-2160. doi: 2110.1016/j. jacc.2008.2102.2059. (2008)
2. Schotten, U., Verheule, S., Kirchhof, P. &Goette, A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 91, 265-325. doi: 210.1152/physrev.00031.02009. (2011)
3. Krahn, A. D., Manfreda, J., Tate, R. B., Mathewson, F. A. &Cuddy, T. E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 98, 476-484 (1995)
4. Benjamin, E. J. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 271, 840-844 (1994)
5. Alonso, A. et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 123, 2946-2953. doi: 2910.1161/CIRCULATIONAHA.2111.020982. Epub 022011 Jun 020986. (2011)
6. Mathew, J. P. et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 291, 1720-1729 (2004)
7. Maisel, W. H., Rawn, J. D. &Stevenson, W. G. Atrial fibrillation after cardiac surgery. Ann Intern Med. 135, 1061-1073 (2001)
8. Ishii, Y. et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation. 111, 2881-2888. Epub 2005 May 2831 (2005)
9. Villareal, R. P. et al. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol. 43, 742-748 (2004)
10. Mariscalco, G. et al. Atrial fibrillation after isolated coronary surgery affects late survival. Circulation. 118, 1612-1618. doi: 1610.1161/CIRCULATIONAHA.1108.777789. Epub 772008 Sep 777729 (2008)
11. Arsenault, K. A. et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 1:CD003611., 10.1002/14651858.CD14003611.pub14651853 (2013)
12. Crystal, E., Connolly, S. J., Sleik, K., Ginger, T. J. &Yusuf, S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-Analysis. Circulation. 106, 75-80 (2002)
13. Eagle, K. A. et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol. 44, e213-310 (2004)
14. Tsikouris, J. P., Kluger, J., Song, J. &White, C. M. Changes in P-wave dispersion and P-wave duration after open heart surgery are associated with the peak incidence of atrial fibrillation. Heart Lung. 30, 466-471 (2001)
15. Franczyk-Skora, B. et al. Acute coronary syndromes in patients with chronic kidney disease. Curr Vasc Pharmacol. 11, 758-767 (2013)
16. Franczyk-Skora, B. et al. Prevention of sudden cardiac death in patients with chronic kidney disease. BMC Nephrol. 13, 162 10.1186/1471-2369-1113-1162. (2012)
17. Soliman, E. Z.et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 159, 1102-1107. doi: 1110.1016/j.ahj.2010.1103.1027. (2010)
18. Korantzopoulos, P. G. &Goudevenos, J. A. Atrial fibrillation in end-stage renal disease: an emerging problem. Kidney Int. 76, 247-249. doi: 210.1038/ki.2009.1144. (2009)
19. Vaziri, S. M., Larson, M. G., Benjamin, E. J. &Levy, D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation. 89, 724-730 (1994)
20. Siragy, H. M. &Carey, R. M. Role of the intrarenal renin-Angiotensin-Aldosterone system in chronic kidney disease. Am J Nephrol 31, 541-550. doi: 510.1159/000313363. Epub 000312010 May 000313318. (2010)
21. Aviles, R. J. et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 108, 3006-3010. Epub 2003 Nov 3017 (2003)
22. Olshansky, B. et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 43, 1201-1208 (2004)
23. Camm, A. J. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 31, 2369-2429. doi: 2310.1093/eurheartj/ehq2278. Epub 2010 Aug 2329 (2010)
24. January, C. T.et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 64, e1-76. doi: 10.1016/j.jacc.2014.1003.1022. Epub 2014 Mar 1028 (2014)
25. Camm, A. J. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. European heart journal 33, 2719-2747, doi: 10.1093/eurheartj/ehs253 (2012)
26. Khatib, R., Joseph, P., Briel, M., Yusuf, S. &Healey, J. Blockade of the renin-Angiotensin-Aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. International journal of cardiology 165, 17-24, doi: 10.1016/j.ijcard.2012.02.009 (2013)
27. Schmieder, R. E. et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. Journal of hypertension 26, 403-411, doi: 10.1097/HJH.0b013e3282f35c67 (2008)
28. Yusuf, S. et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet (London, England) 372, 1174-1183, doi: 10.1016/s0140-6736(08)61242-8 (2008)
29. Maggioni, A. P. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). American heart journal 149, 548-557, doi: 10.1016/j.ahj.2004.09.033 (2005)
30. US Renal Data System: USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (2005)
31. Nimmo, C., Wright, M. &Goldsmith, D. Management of atrial fibrillation in chronic kidney disease: double trouble. American heart journal 166, 230-239, doi: 10.1016/j.ahj.2013.05.010 (2013)
32. Zimmerman, D. et al. Systematic review and meta-Analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association 27, 3816-3822, doi: 10.1093/ndt/gfs416 (2012)
33. Himmelfarb, J., Stenvinkel, P., Ikizler, T. A. &Hakim, R. M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney international 62, 1524-1538, doi: 10.1046/j.1523-1755.2002.00600.x (2002)
34. Vaziri, N. D. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Seminars in nephrology 24, 469-473 (2004)
35. Franczyk-Skora, B., Gluba, A., Olszewski, R., Banach, M. &Rysz, J. Heart function disturbances in chronic kidney disease-echocardiographic indices. Arch Med Sci. 10, 1109-1116. doi: 1110.5114/aoms.2014.47822. (2014)
36. Vazquez, E. et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. The American journal of cardiology 92, 868-871 (2003)
37. Wiesholzer, M. et al. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. American journal of nephrology 21, 35-39, doi: 46216 (2001)
38. Chan, K. E., Lazarus, J. M., Thadhani, R. &Hakim, R. M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. Journal of the American Society of Nephrology: JASN 20, 2223-2233, doi: 10.1681/asn.2009030319 (2009)
39. Winkelmayer, W. C., Liu, J., Setoguchi, S. &Choudhry, N. K. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clinical journal of the American Society of Nephrology: CJASN 6, 2662-2668, doi: 10.2215/cjn.04550511 (2011)
40. Savelieva, I., Kakouros, N., Kourliouros, A. &Camm, A. J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace. 13, 308-328. doi: 310.1093/europace/eur1002. (2011)
41. Schneider, M. P. et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-Analysis. J Am Coll Cardiol. 55, 2299-2307. doi: 2210.1016/j.jacc.2010.2201.2043. (2010)
42. Jibrini, M. B., Molnar, J. &Arora, R. R. Prevention of atrial fibrillation by way of abrogation of the renin-Angiotensin system: a systematic review and meta-Analysis. Am J Ther. 15, 36-43. doi: 10.1097/MJT.1090b1013e31804beb31859. (2008)
43. Goette, A. et al. Angiotensin II-Antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circulation. Arrhythmia and electrophysiology 5, 43-51, doi: 10.1161/circep.111.965178 (2012)
44. Yamashita, T. et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace: European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 13, 473-479, doi: 10.1093/europace/euq439 (2011)
45. Yang, Q., Qi, X. &Li, Y. The preventive effect of atorvastatin on atrial fibrillation: a meta-Analysis of randomized controlled trials. BMC cardiovascular disorders 14, 99, doi: 10.1186/1471-2261-14-99 (2014)
46. Savelieva, I., Kakouros, N., Kourliouros, A. &Camm, A. J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 13, 308-328, doi: 10.1093/europace/eur002 (2011)
47. Dimmer, C.et al. Variations of autonomic tone preceding onset of atrial fibrillation after coronary artery bypass grafting. The American journal of cardiology 82, 22-25 (1998)
48. Sharifov, O. F. et al. Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. Journal of the American College of Cardiology 43, 483-490, doi: 10.1016/j.jacc.2003.09.030 (2004)
49. Sezai, A. et al. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. The Journal of thoracic and cardiovascular surgery 144, 1241-1248, doi: 10.1016/j.jtcvs.2012.06.042 (2012)
50. Ye, S., Zhong, H., Yanamadala, S. &Campese, V. M. Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension. Hypertension 48, 309-315, doi: 10.1161/01.HYP.0000231307.69761.2e (2006)
51. Campese, V. M. &Krol, E. Neurogenic factors in renal hypertension. Current hypertension reports 4, 256-260 (2002)
52. Nangaku, M. &Fujita, T. Activation of the renin-Angiotensin system and chronic hypoxia of the kidney. Hypertens Res. 31, 175-184. doi: 110.1291/hypres.1231.1175. (2008)
53. Lin, T. T. et al. Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis. Kidney international 88, 378-385, doi: 10.1038/ki.2015.96 (2015)
54. Austin, P. C. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 10, 150-161. doi: 110.1002/pst.1433. (2011)